Company intelligence / Profile preview

HanAll Biopharma

Seoul, South Korea

Ownership: Public · 009420
Development stage: Other

Overview

Lead assets include batoclimab (anti-FcRn monoclonal antibody) in Phase 3 for gMG and TED (topline data expected H1 2025), tanfanercept (TNF inhibitor protein) in Phase 3 for dry eye disease (topline 2026), and HL192 (Nurr1 activator) completing Phase 1 for Parkinson's disease (results November 2024). Discontinued TIGIT/TIM-3 oncology programs.[1][9]

Therapeutic areas: EndocrinologyNeurologyDermatologyRheumatologyOphthalmology
Modalities: Monoclonal antibodyProteinSmall molecule
Industry: Biotech

Partnerships

Immunovant (imeroprubart)Harbour BioMed (batoclimab)Roivant Sciences (batoclimab)Daewoong PharmaceuticalNurrOn PharmaceuticalsCSPC NBP Pharmaceuticals

Beyond the preview

Go deeper on HanAll Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HanAll Biopharma.

Explore the full profile